2/25
08:43 pm
crsp
FDA Draft Guidance Puts CRISPR Therapeutics Rare Disease Outlook In Focus [Yahoo! Finance]
Neutral
Report
FDA Draft Guidance Puts CRISPR Therapeutics Rare Disease Outlook In Focus [Yahoo! Finance]
2/19
07:30 am
crsp
CRISPR Therapeutics touts zugo-cel CAR-T gains, eyes autoimmune expansion at Citi oncology summit [Yahoo! Finance]
Low
Report
CRISPR Therapeutics touts zugo-cel CAR-T gains, eyes autoimmune expansion at Citi oncology summit [Yahoo! Finance]
2/18
10:41 am
crsp
Should You Buy Shares of CRISPR Therapeutics in February? [Yahoo! Finance]
Low
Report
Should You Buy Shares of CRISPR Therapeutics in February? [Yahoo! Finance]
2/17
11:55 am
crsp
CRISPR Therapeutics Q4: The Elite Time To Buy Is In 2027 [Seeking Alpha]
Low
Report
CRISPR Therapeutics Q4: The Elite Time To Buy Is In 2027 [Seeking Alpha]
2/17
09:09 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
CRISPR Therapeutics (NASDAQ:CRSP) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.
2/16
08:05 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
CRISPR Therapeutics (NASDAQ:CRSP) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
2/15
02:13 am
crsp
Is CRISPR Therapeutics' (CRSP) Casgevy Momentum Enough to Offset Steep 2025 Revenue Declines? [Yahoo! Finance]
Low
Report
Is CRISPR Therapeutics' (CRSP) Casgevy Momentum Enough to Offset Steep 2025 Revenue Declines? [Yahoo! Finance]
2/14
09:06 am
crsp
Crispr Therapeutics price target raised to $82 from $80 at Needham [Yahoo! Finance]
Low
Report
Crispr Therapeutics price target raised to $82 from $80 at Needham [Yahoo! Finance]
2/14
09:06 am
crsp
Crispr Therapeutics price target raised to $74 from $62 at Evercore ISI [Yahoo! Finance]
Low
Report
Crispr Therapeutics price target raised to $74 from $62 at Evercore ISI [Yahoo! Finance]
2/14
08:00 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) was given a new $76.00 price target on by analysts at Chardan Capital.
Low
Report
CRISPR Therapeutics (NASDAQ:CRSP) was given a new $76.00 price target on by analysts at Chardan Capital.
2/13
10:16 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
Low
Report
CRISPR Therapeutics (NASDAQ:CRSP) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
2/13
09:09 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) had its "hold" rating reaffirmed by analysts at TD Cowen.
Medium
Report
CRISPR Therapeutics (NASDAQ:CRSP) had its "hold" rating reaffirmed by analysts at TD Cowen.
2/13
08:02 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) had its price target raised by analysts at Needham & Company LLC from $80.00 to $82.00. They now have a "buy" rating on the stock.
Medium
Report
CRISPR Therapeutics (NASDAQ:CRSP) had its price target raised by analysts at Needham & Company LLC from $80.00 to $82.00. They now have a "buy" rating on the stock.
2/12
04:52 pm
crsp
CRISPR Therapeutics GAAP EPS of -$1.37 misses by $0.22, revenue of $0.86M misses by $3.16M [Seeking Alpha]
Medium
Report
CRISPR Therapeutics GAAP EPS of -$1.37 misses by $0.22, revenue of $0.86M misses by $3.16M [Seeking Alpha]
2/12
04:30 pm
crsp
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Medium
Report
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
2/11
02:02 pm
crsp
Studies test whether gene-editing can fix high cholesterol. For now, take your medicine [Yahoo! Finance Canada]
Low
Report
Studies test whether gene-editing can fix high cholesterol. For now, take your medicine [Yahoo! Finance Canada]
2/1
03:42 am
crsp
CRISPR Therapeutics Milestones And ARK Backing Contrast With Valuation Gap [Yahoo! Finance]
Low
Report
CRISPR Therapeutics Milestones And ARK Backing Contrast With Valuation Gap [Yahoo! Finance]
1/30
09:25 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) had its price target lowered by analysts at Citizens Jmp from $86.00 to $80.00. They now have a "market outperform" rating on the stock.
Medium
Report
CRISPR Therapeutics (NASDAQ:CRSP) had its price target lowered by analysts at Citizens Jmp from $86.00 to $80.00. They now have a "market outperform" rating on the stock.
1/30
07:17 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
CRISPR Therapeutics (NASDAQ:CRSP) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
1/29
01:11 pm
crsp
Forget AI Stocks: This Biotech Could Cure What AI Can't Touch [Yahoo! Finance]
Low
Report
Forget AI Stocks: This Biotech Could Cure What AI Can't Touch [Yahoo! Finance]
1/29
07:31 am
crsp
BofA is Bullish on CRISPR Therapeutics AG (CRSP) [Yahoo! Finance]
Low
Report
BofA is Bullish on CRISPR Therapeutics AG (CRSP) [Yahoo! Finance]
1/27
10:38 am
crsp
Is CRISPR Therapeutics (CRSP) Still Attractive After A 67% Five Year Share Price Decline [Yahoo! Finance]
Low
Report
Is CRISPR Therapeutics (CRSP) Still Attractive After A 67% Five Year Share Price Decline [Yahoo! Finance]
1/27
05:38 am
crsp
Assessing CRISPR Therapeutics' Valuation As Recent Trading Puts CRSP Back In Focus [Yahoo! Finance]
Low
Report
Assessing CRISPR Therapeutics' Valuation As Recent Trading Puts CRSP Back In Focus [Yahoo! Finance]
1/23
09:19 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) had its price target lowered by analysts at Bank of America Corporation from $90.00 to $89.00. They now have a "buy" rating on the stock.
Medium
Report
CRISPR Therapeutics (NASDAQ:CRSP) had its price target lowered by analysts at Bank of America Corporation from $90.00 to $89.00. They now have a "buy" rating on the stock.
1/15
08:09 pm
crsp
CRISPR Therapeutics AG (CRSP) Stock Declines While Market Improves: Some Information for Investors [Yahoo! Finance]
Low
Report
CRISPR Therapeutics AG (CRSP) Stock Declines While Market Improves: Some Information for Investors [Yahoo! Finance]